Fasiglifam (TAK-875) inhibits hepatobiliary transporters: A possible factor contributing to fasiglifam-induced liver injury

Drug Metabolism and Disposition

Volumn 43, Issue 11, 2015, Pages 1751-1759

  Li, Xiuli ^a   Zhong, Kan ^a   Guo, Zitao ^a   Zhong, Dafang ^a   Chen, Xiaoyan ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BILE ACID; BILE SALT EXPORT PUMP; BILIRUBIN; CARRIER PROTEIN; FASIGLIFAM; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; TAUROCHOLIC ACID; VINBLASTINE; BENZOFURAN DERIVATIVE; COTRANSPORTER; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; ORGANIC ANION TRANSPORTER; SODIUM-BILE ACID COTRANSPORTER; SULFONE; TAK-875;

ANIMAL CELL; ARTICLE; BILE ACID BLOOD LEVEL; BILIARY CLEARANCE; BILIARY EXCRETION; BILIRUBIN BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; EMBRYO; HOMEOSTASIS; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MDCK CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT; TOXIC HEPATITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DOG; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; HEPATOBILIARY SYSTEM; LIVER CELL; MALE; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BENZOFURANS; BILIARY TRACT; CELLS, CULTURED; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; HEK293 CELLS; HEPATOCYTES; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; RATS; RATS, SPRAGUE-DAWLEY; SULFONES; SYMPORTERS;

EID: 84946213017     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.064121     Document Type: Article

References (41)

1. Alrefai WA and Gill RK (2007) Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 24:1803-1823.
2. Annaert P, Ye ZW, Stieger B, and Augustijns P (2010) Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40:163-176.
3. Annaert PP, Turncliff RZ, Booth C.L., Thakker DR, and Brouwer KL (2001) P-glycoproteinmediated in vitro biliary excretion in sandwich-cultured rat hepatocytes. Drug Metab Dispos 29:1277-1283.
4. Ansede JH, Smith WR, Perry C.H., St Claire RL, 3rd, and Brouwer KR (2010) An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes. Drug Metab Dispos 38:276-280.
5. Campbell SD, de Morais SM, and Xu JJ (2004) Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact 150:179-187.
6. Chang JH, Plise E, Cheong J., Ho Q, and Lin M (2013) Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia. Mol Pharm 10:3067-3075.
7. Chiou WJ, de Morais SM, Kikuchi R, Voorman RL, Li X, and Bow DA (2014) In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. Xenobiotica 44:276-282.
8. Cui Y, König J, Leier I., Buchholz U, and Keppler D (2001) Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276: 9626-9630.
9. Dawson PA, Lan T, and Rao A (2009) Bile acid transporters. J Lipid Res 50:2340-2357.
10. Evers R, de Haas M, Sparidans R, Beijnen J., Wielinga PR, Lankelma J, and Borst P (2000) Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 83:375-383.
11. Evers R, Kool M, van Deemter L, Janssen H, Calafat J., Oomen LC, Paulusma CC, Oude Elferink RP, Baas F, and Schinkel AH, et al. (1998) Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 101:1310-1319.
12. Fattinger K, Funk C, Pantze M., Weber C, Reichen J, Stieger B., and Meier PJ (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223-231.
13. Funk C, Pantze M, Jehle L., Ponelle C, Scheuermann G, Lazendic M., and Gasser R (2001a) Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167:83-98.
14. Funk C, Ponelle C, Scheuermann G., and Pantze M (2001b) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 59: 627-635.
15. Hansen TW (2001) Bilirubin brain toxicity. J Perinatol 21(Suppl 1):S48-S62.
16. Hofmann AF (1999) The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 159:2647-2658.
17. Jacquemin E, Hagenbuch B, Stieger B., Wolkoff AW, and Meier PJ (1994) Expression cloning of a rat liver Na(+)-independent organic anion transporter. Proc Natl Acad Sci USA 91: 133-137.
18. Jedlitschky G, Leier I, Buchholz U., Hummel-Eisenbeiss J, Burchell B, and Keppler D (1997) ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem J 327:305-310.
19. Keppler D (2014) The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. Drug Metab Dispos 42:561-565.
20. Klaassen CD and Aleksunes LM (2010) Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 62:1-96.
21. Köck K and Brouwer KL (2012) A perspective on efflux transport proteins in the liver. Clin Pharmacol Ther 92:599-612.
22. Kostrubsky VE, Strom SC, Hanson J, Urda E., Rose K, Burliegh J, Zocharski P., Cai H, Sinclair JF, and Sahi J (2003) Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol Sci 76:220-228.
23. Leifke E, Naik H, Wu J., Viswanathan P, Demanno D, Kipnes M., and Vakilynejad M (2012) A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther 92: 29-39.
24. Leslie EM, Watkins PB, Kim R.B., and Brouwer KL (2007) Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther 321:1170-1178.
25. Li C, Zhang L, Zhou L., Wo SK, Lin G, and Zuo Z (2012) Comparison of intestinal absorption and disposition of structurally similar bioactive flavones in Radix Scutellariae. AAPS J 14: 23-34.
26. Liu X, Chism JP, LeCluyse E.L., Brouwer KR, and Brouwer KL (1999a) Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 27: 637-644.
27. Liu X, LeCluyse EL, Brouwer K.R., Gan LS, Lemasters JJ, Stieger B, Meier P.J., and Brouwer KL (1999b) Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am J Physiol 277:G12-G21.
28. Maillette de Buy Wenniger L and Beuers U (2010) Bile salts and cholestasis. Dig Liver Dis 42: 409-418.
29. Mayer M, Nudurupati S, Peng X., and Marcinak J (2014) Evaluation of the pharmacokinetics and safety of a single oral dose of fasiglifam in subjects with normal or varying degrees of impaired renal function. Drugs R D 14:273-282.
30. Meier-Abt F., Faulstich H, and Hagenbuch B (2004) Identification of phalloidin uptake systems of rat and human liver. Biochim Biophys Acta 1664:64-69.
31. Meier PJ, Eckhardt U, Schroeder A., Hagenbuch B, and Stieger B (1997) Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26: 1667-1677.
32. Naik H, Vakilynejad M, Wu J., Viswanathan P, Dote N, Higuchi T., and Leifke E (2012) Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 52:1007-1016.
33. Negoro N, Sasaki S, Mikami S., Ito M, Suzuki M, Tsujihata Y., Ito R, Harada A, Takeuchi K., and Suzuki N, et al. (2010) Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett 1:290-294.
34. Satlin LM, Amin V, and Wolkoff AW (1997) Organic anion transporting polypeptide mediates organic anion/HCO3-exchange. J Biol Chem 272:26340-26345.
35. Smith MT (2003) Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 16:679-687.
36. Tian X, Zamek-Gliszczynski MJ, Zhang P., and Brouwer KL (2004) Modulation of multidrug resistance-associated protein 2 (Mrp2) and Mrp3 expression and function with small interfering RNA in sandwich-cultured rat hepatocytes. Mol Pharmacol 66:1004-1010.
37. Trauner M, Arrese M, Soroka C.J., Ananthanarayanan M., Koeppel TA, Schlosser SF, Suchy FJ, Keppler D, and Boyer JL (1997) The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 113: 255-264.
38. Trauner M and Boyer JL (2003) Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 83:633-671.
39. Yang K, Woodhead JL, Watkins P.B., Howell BA, and Brouwer KL (2014) Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity. Clin Pharmacol Ther 96:589-598.
40. Zamek-Gliszczynski M.J., Hoffmaster KA, Tweedie D.J., Giacomini KM, and Hillgren KM (2012) Highlights from the International Transporter Consortium second workshop. Clin Pharmacol Ther 92:553-556.
41. Zamek-Gliszczynski M.J., Xiong H, Patel N.J., Turncliff RZ, Pollack GM, and Brouwer KL (2003) Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver. J Pharmacol Exp Ther 304:801-809.